Abstract
Berberine is an alkaloid found in plants. It has neuroprotective, anti-inflammatory and hypolipidemic activities. The research proves that it also strongly impacts carbohydrate metabolism. The compound also protects pancreatic β-cells and increases sensitivity to insulin in peripheral tissues via the induction of GLUT-1, GLUT-4 and insulin type 1 (Ins-1) receptors activity. It also stimulates glycolysis and leads to a decrease in insulin resistance by macrophages polarization, lipolytic processes induction and energy expenditure enhancement (by reducing body mass and limiting insulin resistance caused by obesity). In liver berberine inhibits FOX01, SREBP1 and ChREBP pathways, and HNF-4α (hepatocyte nuclear factor 4 alpha) mRNA that hinder gluconeogenesis processes. In the intestines it blocks α-glucosidase contributing to glucose absorption decrease. Its interference in intestinal flora reduces levels of monosaccharides and suppresses diabetes mellitus complications development.
Keywords: Berberine, alkaloid, diabetes mellitus, metabolism, nutrition, review.
Graphical Abstract
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Berberine in the Treatment of Diabetes Mellitus: A Review
Volume: 21 Issue: 8
Author(s): Aleksandra Baska*, Kamil Leis and Przemysław Gałązka
Affiliation:
- Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, ul. Jagiellonska 13/15, 85-090Bydgoszcz,Poland
Keywords: Berberine, alkaloid, diabetes mellitus, metabolism, nutrition, review.
Abstract: Berberine is an alkaloid found in plants. It has neuroprotective, anti-inflammatory and hypolipidemic activities. The research proves that it also strongly impacts carbohydrate metabolism. The compound also protects pancreatic β-cells and increases sensitivity to insulin in peripheral tissues via the induction of GLUT-1, GLUT-4 and insulin type 1 (Ins-1) receptors activity. It also stimulates glycolysis and leads to a decrease in insulin resistance by macrophages polarization, lipolytic processes induction and energy expenditure enhancement (by reducing body mass and limiting insulin resistance caused by obesity). In liver berberine inhibits FOX01, SREBP1 and ChREBP pathways, and HNF-4α (hepatocyte nuclear factor 4 alpha) mRNA that hinder gluconeogenesis processes. In the intestines it blocks α-glucosidase contributing to glucose absorption decrease. Its interference in intestinal flora reduces levels of monosaccharides and suppresses diabetes mellitus complications development.
Export Options
About this article
Cite this article as:
Baska Aleksandra*, Leis Kamil and Gałązka Przemysław , Berberine in the Treatment of Diabetes Mellitus: A Review, Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21 (8) . https://dx.doi.org/10.2174/1568026620666201022144405
DOI https://dx.doi.org/10.2174/1568026620666201022144405 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Age Related Macular Degeneration and Visual Disability
Current Drug Targets Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Treating Diabetes Mellitus in Older and Oldest Old Patients
Current Pharmaceutical Design Gastrointestinal Hemorrhage is Associated with Mortality after Acute Ischemic Stroke
Current Neurovascular Research Effects of Imidazolic Agonism on Blood Pressure, Sympathetic Activity, Left Ventricular Hypertrophy and Insulin Resistance
Current Hypertension Reviews Screening Haemostasis – Looking for Global Assays: The Overall Haemostasis Potential (OHP) Method – A Possible Tool for Laboratory Investigation of Global Haemostasis in Both Hypo- and Hypercoagulable Conditions
Current Vascular Pharmacology Molecular and Pathophysiological Mechanisms of Diabetic Retinopathy in Relation to Adhesion Molecules
Current Diabetes Reviews The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Enzymes as Target Antigens of Liver-Specific Autoimmunity: The Case of Cytochromes P450s
Current Medicinal Chemistry Editorial [Hot Topic: Nitric Oxide and Hydrogen Sulfide - Contribution of Gaseous Messengers to the Cardiovascular Control (Guest Editor: Sona Cacanyiova)]
Current Pharmaceutical Biotechnology Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Intravitreal Injections and Diabetic Macular Edema: Actual and New Therapeutic Options
Current Diabetes Reviews High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Critical Role of Epigenetic Regulation in Developmental Programming of Higher Organisms
Current Genomics Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Long-Term Exposure to Ambient Hydrocarbons Increases Dementia Risk in People Aged 50 Years and above in Taiwan
Current Alzheimer Research Glucose Transporter and Na+ / glucose Cotransporter as Molecular Targets of Anti-Diabetic Drugs
Current Medicinal Chemistry Transplantation of Genetically Modified Haematopoietic Stem Cells to Induce Antigen-Specific Tolerance as a Cure for Autoimmune Diseases
Current Stem Cell Research & Therapy